← All trials
NCT05638165
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2021
- Primary completion
- Nov 20, 2021
- Completion date
- Nov 20, 2021
- First posted
- Dec 6, 2022
- Last posted
- Dec 19, 2022
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovaCell Technology Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.